Zhongsheng Pharmaceutical announced that ZSP1601 tablets, a class of innovative drugs independently developed by the company's holding subsidiary Zhongsheng Ruichuang, were included in the breakthrough treatment program by the Drug Evaluation Center of the State Drug Administration, and the proposed indication is metabolism-related steatohepatitis. ZSP1601 tablets are the first class of innovative drugs to treat MASH with independent global intellectual property rights and a new mechanism of action, and are a major national new drug creation project. The phase IIb clinical trial of ZSP1601 tablets to treat MASH has obtained positive data results, and the main efficacy end point of pathologic improvement was reached after 48 weeks of treatment. At the same time, it achieves the triple benefits of fighting fibrosis, reducing liver fat content, and improving liver enzymes. It works fast, has stable effects, and has excellent safety.

Zhongsheng Pharmaceutical announced that ZSP1601 tablets, a class of innovative drugs independently developed by the company's holding subsidiary Zhongsheng Ruichuang, were included in the breakthrough treatment program by the Drug Evaluation Center of the State Drug Administration, and the proposed indication is metabolism-related steatohepatitis. ZSP1601 tablets are the first class of innovative drugs to treat MASH with independent global intellectual property rights and a new mechanism of action, and are a major national new drug creation project. The phase IIb clinical trial of ZSP1601 tablets to treat MASH has obtained positive data results, and the main efficacy end point of pathologic improvement was reached after 48 weeks of treatment. At the same time, it achieves the triple benefits of fighting fibrosis, reducing liver fat content, and improving liver enzymes. It works fast, has stable effects, and has excellent safety.